Shots:

• Pieris to receive $10M upfront and is eligible to receive $353M in development- regulatory- and commercial based milestones along with royalties on sales of PRS-342. Pieris will also contribute an undisclosed amount for manufacturing activities
• Boston to get exclusive worldwide rights to develop PRS-342 and will be primarily responsible for the development of the program- with both parties collaborating during the IND-enabling stage
• PRS-342 is a 4-1BB/GPC3 preclinical immuno-oncology Anticalin-Ab bispecific fusion protein

  Ref: Business Wire | Image: Mass Device